HER2-Positive Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
HER2-Positive Metastatic Colorectal Cancer Market Outlook
Thelansis’s “HER2-Positive Metastatic
Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential HER2-Positive
Metastatic Colorectal Cancer treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
HER2-Positive
Metastatic Colorectal Cancer Overview
Metastatic
colorectal cancer (mCRC) stands as a prominent contributor to cancer-related
deaths, with approximately 30–40% of patients presenting with metastatic
disease at diagnosis. Notably, HER2 positivity is rare, affecting less than 5%
of our mCRC patient cohort. The detection of HER2 overexpression in CRC
involves immune-histochemical (IHC) staining for HER2 protein, in-situ
hybridization (ISH) for gene amplification, or reverse transcription polymerase
chain reaction (RT-PCR) for HER2 RNA overexpression. Furthermore, HER2
amplification and mutations in KRAS, NRAS, and BRAF typically do not co-occur
in advanced CRC, with KRAS exon two wild-type mCRC exhibiting a potential
enrichment for HER2 amplification, found in approximately 4% to 9% of cases.
The overall survival duration is approximately 24.1 months, ranging from 20.3
to 36.7 months. A noteworthy advancement in treatment is the FDA approval of
the Tukysa and Herceptin combination, marking the first approved therapy for
HER2-positive mCRC.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment